Placebo News and Research

RSS

Laurent reports positive topline results from LAU-7b Phase 1b trial in adult CF patients

Laurent Pharmaceuticals Inc. announced today positive topline results from a Phase 1b clinical trial with LAU-7b in adult CF patients. LAU-7b is a novel oral formulation of fenretinide, a synthetic retinoid investigated for its lipid modulating properties and potential to address the aberrant inflammatory response in CF.

15 Jun 2015

Juniper announces enrollment of first patient in COL-1077 Phase II trial to reduce pain during endometrial biopsy

Juniper Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of therapeutics for women's health, announced today the first patient has been enrolled in a Phase II clinical trial of COL-1077, a 10% lidocaine bioadhesive gel that is intended as an acute-use anesthetic during minimally invasive gynecologic procedures.

15 Jun 2015

Clinical studies confirm safety, efficacy of opicapone in Parkinson’s disease patients

BIAL is presenting 11 research posters at the 19th International Congress of Parkinson's Disease and Movement Disorders (June 14–15, San Diego, CA). These evaluate the safety and efficacy of opicapone (BIA 9-1067), a novel once-daily catechol-O-methyltransferase (COMT) inhibitor for use as adjunctive therapy in levodopa-treated Parkinson’s disease patients with end of dose motor fluctuations.

15 Jun 2015

Novartis announces FDA approval of Promacta for treatment of children with chronic ITP

Novartis announced today that the US Food and Drug Administration has approved Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was approved by the FDA in 2008 for use in adult patients with the same condition.

15 Jun 2015

Vitamin D supplementation may treat Crohn’s disease

New research published in this month’s edition of United European Gastroenterology Journal suggests that supplementation with vitamin D may impact on the intestinal barrier dysfunction associated with Crohn’s disease, and could have a role in the treatment of the condition.

15 Jun 2015

Hydroxychloroquine drug fails to reduce mild-moderate pain from primary hand osteoarthritis

The results of an interventional trial presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that use of the disease-modifying anti-rheumatic drug hydroxychloroquine for 24 weeks did not diminish mild-moderate pain from primary hand osteoarthritis (OA).

14 Jun 2015

Vitamin D supplementation may affect intestinal barrier dysfunction associated with Crohn's disease

New research published in this month's edition of United European Gastroenterology journal suggests that supplementation with vitamin D may impact on the intestinal barrier dysfunction associated with Crohn's disease, and could have a role in the treatment of the condition.

13 Jun 2015

ADHD drug improves cognitive decline in menopausal women

According to a new study, women experiencing difficulty with time management, attention, organization, memory, and problem solving - often referred to as executive functions - related to menopause may find improvement with a drug already being used to treat attention deficit hyperactivity disorder (ADHD).

12 Jun 2015

NSAIDs significantly inhibit ovulation in women with mild musculoskeletal pain

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) show that diclofenac, naproxen and etoricoxib significantly inhibit ovulation in women with mild musculoskeletal pain. Of the women receiving NSAIDs, only 6.3 percent (diclofenac), 25 percent (naproxen) and 27.3 percent (etoricoxib) ovulated, compared with 100 percent of the control group.

12 Jun 2015

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Tioga Pharmaceuticals, a clinical stage biotechnology company, today announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States.

11 Jun 2015

Ixekizumab drug shows quick and extensive improvements in patients with psoriasis

A University of Manchester led trial of a new psoriasis drug has resulted in 40 percent of people showing a complete clearance of psoriatic plaques after 12 weeks of treatment and over 90 percent showing improvement.

11 Jun 2015

UC San Diego researchers launch clinical trial to evaluate safety, efficacy of suramin drug for autism

Researchers at the University of California, San Diego School of Medicine have launched a clinical trial to investigate the safety and efficacy of an unprecedented drug therapy for autism.

11 Jun 2015

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen today announced that the Company will discuss the data supporting the Repatha (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC).

10 Jun 2015

LEO Pharma reports encouraging data from PSO-FAST clinical trial of Enstilar for psoriasis treatment

LEO Pharma A/S today announced that new data being presented at the 23rd World Congress of Dermatology shows aerosol foam Enstilar® (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g), the Company's dual-action investigational aerosol foam for the treatment of psoriasis vulgaris, provided rapid itch relief and improvements in itch-related sleep loss for patients suffering from psoriasis.

10 Jun 2015

INS announces winners of inaugural best abstract competition at 12th World Congress

The International Neuromodulation Society (INS) announced winners today of its inaugural best abstract competition at the 12th World Congress in Montreal.

10 Jun 2015

Combining lifestyle modification with metformin could help women manage polycystic ovary syndrome

A systematic review publishing today in the journal Human Reproduction Update has found that women who suffer from polycystic ovary syndrome (PCOS) could manage some of the symptoms by combining a change in lifestyle with taking the drug metformin.

10 Jun 2015

CHIMES-E study: NeuroAiD provides long-term benefits to patients after ischemic stroke

Moleac is pleased to announce the release of the CHIMES-E study results published online in the journal Cerebrovascular Diseases. It provides convincing data on NeuroAiD which confirm its persistent long-term benefits on patients' recovery after an ischemic stroke.

10 Jun 2015

Danish nasal filter prevents pollen inhalation, reduces symptoms of hay fever

Getting through the pollen season can now become easier for some of the approximately 500 million people worldwide who suffer from sneezing and a runny nose, watery eyes and drowsiness during the allergy season (seasonal allergic rhinitis).

10 Jun 2015

Phase 2 study of AR101 meets primary endpoint in patients with peanut allergy

Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that a Phase 2 study (ARC001) evaluating the company's lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively.

10 Jun 2015

New clinical trial compares outcomes of vitamin D supplementation on pediatric burn patients

Deficiency of vitamin D is a common problem for patients with severe burn injuries and can lead to further health compromise. However, there are no evidence-based guidelines for vitamin D replenishment in such patients.

10 Jun 2015

Placebo News and Research

Laurent reports positive topline results from LAU-7b Phase 1b trial in adult CF patients

Juniper announces enrollment of first patient in COL-1077 Phase II trial to reduce pain during endometrial biopsy

Clinical studies confirm safety, efficacy of opicapone in Parkinson’s disease patients

Novartis announces FDA approval of Promacta for treatment of children with chronic ITP

Vitamin D supplementation may treat Crohn’s disease

Hydroxychloroquine drug fails to reduce mild-moderate pain from primary hand osteoarthritis

Vitamin D supplementation may affect intestinal barrier dysfunction associated with Crohn's disease

ADHD drug improves cognitive decline in menopausal women

NSAIDs significantly inhibit ovulation in women with mild musculoskeletal pain

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Ixekizumab drug shows quick and extensive improvements in patients with psoriasis

UC San Diego researchers launch clinical trial to evaluate safety, efficacy of suramin drug for autism

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

LEO Pharma reports encouraging data from PSO-FAST clinical trial of Enstilar for psoriasis treatment

INS announces winners of inaugural best abstract competition at 12th World Congress

Combining lifestyle modification with metformin could help women manage polycystic ovary syndrome

CHIMES-E study: NeuroAiD provides long-term benefits to patients after ischemic stroke

Danish nasal filter prevents pollen inhalation, reduces symptoms of hay fever

Phase 2 study of AR101 meets primary endpoint in patients with peanut allergy

New clinical trial compares outcomes of vitamin D supplementation on pediatric burn patients

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News